Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: October 28, 2025
Reporting Period: Single event date (October 28, 2025)
Business Overview: The company develops diagnostic technologies, specifically focusing on flow cytometry combined with fluorescent probes to detect cellular and molecular signatures of lung diseases.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing reports a material non-financial event: the acceptance of a patent application by the Australian Patent Office.
- Patent Application: AU 2019253111
- Title: "System and Method for Determining Lung Health"
- Technology: Methods utilizing flow cytometry and fluorescent probes/molecular tags to identify signatures of multiple lung diseases.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, forward-looking outlooks, or specific risk factors beyond the standard disclosure of the patent acceptance. The event is presented as a positive development in the company's intellectual property portfolio.
Investor Verification Checklist
- Verify the status and scope of patent application AU 2019253111 in the Australian Patent Office database.
- Review the attached press release (Exhibit 99.1) for detailed technical specifications of the lung health detection method.
- Confirm the commercialization timeline for the patented technology, as this filing only confirms acceptance of the application, not final grant or revenue generation.
- Check recent 10-K or 10-Q filings for the company's current cash position and runway, as this 8-K contains no financial data.